Metraipolis › archive › dc_1fd0186bd09c

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes — Europe PMC PMID:42755040

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42755040
DOI
10.1093/rheumatology/keag515
License (as archived)
solo-consultazione
Archived
2026-10-09T06:27:14.330Z
SHA-256 of the archived text
ebaae7801d4bd25cef884c7743ff11f8021d0fa0dd6313fe935f36b9827c3d12
Stable URL of this page
https://metraipolis.com/documento/dc_1fd0186bd09c

How to cite

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes — Europe PMC PMID:42755040 — Europe PMC (en), https://europepmc.org/article/MED/42755040 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1fd0186bd09c (Metraipolis archive dc_1fd0186bd09c, sha256 ebaae7801d4bd25cef884c7743ff11f8021d0fa0dd6313fe935f36b9827c3d12)
BibTeX
@misc{dc1fd0186bd09c,
  title = {First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes — Europe PMC PMID:42755040},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42755040},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1fd0186bd09c; sha256 ebaae7801d4bd25cef884c7743ff11f8021d0fa0dd6313fe935f36b9827c3d12},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42755040. Agents can read the archived copy with the MCP tool read_document.